Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSD | A5PKW4 | 7/20 | 0.53 |
| ▸ | ARF6 | P62330 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PLTP | P55058 | 1/20 | 0.41 |
| ▸ | SLC27A2 | O14975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17298691 | 0.97 | PSD (0.54) | PSDARF6MAPTMEN1KMT2A | |
| SCHEMBL14899468 | 0.92 | ARF6 (0.56) | PSDARF6MAPTMEN1KMT2A | |
| SCHEMBL13516182 | 0.91 | KDM4E (0.48) | PSDARF6KDM4ELMNAHTT | |
| SCHEMBL13516218 | 0.88 | ARF6 (0.65) | PSDARF6SLC27A2 | |
| SCHEMBL14212973 | 0.88 | ARF6 (0.46) | PSDARF6KDM4ELMNAHTT | |
| SCHEMBL13516531 | 0.88 | KDM4E (0.47) | PSDARF6MEN1KMT2AKDM4E | |
| SCHEMBL19084601 | 0.87 | ARF6 (0.54) | PSDARF6KDM4E | |
| SCHEMBL19084591 | 0.85 | ARF6 (0.54) | PSDARF6SLC27A2 | |
| SCHEMBL14235192 | 0.85 | ARF6 (0.43) | PSDARF6KDM4ELMNAHTT | |
| SCHEMBL19084518 | 0.84 | PSD (0.48) | PSDARF6MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849901-B2 | Arf6 inhibitors and methods of synthesis and use thereof | NAVIGEN, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | NAVIGEN, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | NAVIGEN, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-8431582-B2 | Inhibitors of fatty acid uptake and methods of use | NUTECH VENTURES (US) | 2013-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189405-A1 | ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF | ARF6, ARF1, ARFIP2 | PSD 211/4885ARF6 1/4885MAPT 2995/4885 |
| US-10849901-B2 | Arf6 inhibitors and methods of synthesis and use thereof | ARF6, ARF1, ARFIP2 | PSD 211/4885ARF6 1/4885MAPT 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.